HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC

HOOKIPA Pharma Inc.

2023-Q3 EPS reported -$0.64 revenue$12,722,000

Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.
Net loss of $19.1M vs $18.3M YoY; R&D expenses increased to $24.6M from $18.3M.
Cash and equivalents $108.1M as of Sep 30, 2023, down from $113.4M at Dec 31, 2022.
HB-200 + pembro achieved 42% ORR in 19 evaluable CPI-naïve patients, doubling historical 19% for pembro alone.
Anticipated milestones: Phase 2 HB-200 data H1 2024, randomized trial mid-2024; IND filings for HB-700 (H1 2024) and HB-500 (Q4 2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HOOKIPA Pharma Inc. reported third quarter of 2023 results: revenue $6.9 million, net income $19.1 million.

Period: third quarter of 2023
Revenue: $6.9 million
Net income: $19.1 million
Result: reported results

Exact text from the filing

The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023. Revenue: Revenue was $6.9 million for the three months ended September 30, 2023 and $2.2 million for the three months ended September 30, 2022. This increase was primarily due to higher partial recognition of the

View on SEC.gov

Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.